Investors who lost money on Lantheus Holdings, Inc.(LNTH) should contact The Gross Law Firm about pending Class Action - LNTH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy LNTH?
Source: PRnewswire
Class Action Notice: The Gross Law Firm is notifying shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH) about a class action lawsuit for those who purchased shares between February 26, 2025, and August 5, 2025, encouraging them to register for potential lead plaintiff appointment.
Allegations Against Lantheus: The complaint alleges that Lantheus made false statements regarding its revenue outlook and growth potential, misleading investors about the market dynamics affecting its product, Pylarify.
Registration Deadline: Shareholders are urged to register by November 10, 2025, to participate in the class action, with no cost or obligation to join.
Firm's Commitment: The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices, seeking recovery for losses due to misleading statements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 68.720
Low
70.00
Averages
82.17
High
105.00
Current: 68.720
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantheus to Host Q4 and Full Year 2025 Financial Results Call
- Conference Call Announcement: Lantheus Holdings will host a conference call on February 26, 2026, at 8:00 a.m. ET to discuss its financial and operational results for Q4 and the full year of 2025, aiming to provide investors with the latest performance insights.
- Registration Recommendation: The company encourages participants to register online 15 minutes in advance to avoid delays at the start of the call, reflecting its commitment to enhancing the investor experience.
- Replay Availability: A replay will be accessible approximately two hours after the call concludes and will be archived on the same webpage for at least 30 days, allowing investors who could not attend live to access the information, thereby increasing transparency.
- Company Background: Lantheus is a leading radiopharmaceutical-focused company with 70 years of experience, dedicated to enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes through innovative scientific solutions.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
Lantheus Sells SPECT Business to SHINE, Focuses on PET Radiodiagnostics
- Business Sale: Lantheus has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, which includes diagnostic agents like TechneLite® and NEUROLITE®, marking a strategic shift for the company.
- Focus on Innovation: Post-sale, Lantheus will concentrate on its expanding portfolio of PET radiodiagnostics and microbubbles, which is expected to enhance its competitiveness and innovation in the radiopharmaceutical market.
- Advisory Support: Solomon Partners Securities acted as the financial advisor for Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP provided legal support, ensuring a smooth transaction process.
- Market Outlook: By divesting its SPECT business, Lantheus aims to optimize resource allocation and focus on its high-growth potential PET product line to meet increasing market demand and improve patient treatment outcomes.
See More
Lantheus Sells SPECT Business to SHINE, Focuses on PET Diagnostics
- Business Sale Completed: Lantheus has successfully sold its single photon emission computed tomography (SPECT) business to SHINE Technologies, including several diagnostic agents and the North Billerica, Massachusetts manufacturing facility, which is expected to allow Lantheus to focus more on its rapidly growing PET radiodiagnostics portfolio.
- Strategic Shift: Through this transaction, Lantheus will reallocate resources to innovative PET radiopharmaceuticals and microbubble products, thereby enhancing its competitiveness in the radiopharmaceutical market and driving future R&D advancements.
- Advisory Support: In this transaction, Solomon Partners Securities acted as Lantheus's financial advisor, while Foley Hoag LLP and Ropes & Gray LLP provided legal support, and Ernst & Young LLP handled financial and tax consulting, ensuring a smooth transaction process.
- Market Positioning Optimization: The divestiture of the SPECT business will enable Lantheus to leverage its expertise in radiopharmaceuticals more effectively, further solidifying its market position in cardiac and cancer diagnostics, which is expected to have a positive impact on the company's long-term growth.
See More
Nitorum Capital Exits Lantheus Holdings Stake with $28.2 Million Transaction
- Complete Exit: Nitorum Capital sold 344,444 shares of Lantheus Holdings during Q3 for an estimated $28.2 million, marking a complete exit from the company and reflecting a cautious outlook on its future performance.
- Asset Management Shift: Following this transaction, Nitorum's 13F reportable assets under management decreased to $569.28 million, indicating a significant adjustment in its investment portfolio that may impact future investment strategies.
- Earnings Pressure: Despite Lantheus reporting $384 million in Q3 revenue and nearly $95 million in free cash flow, its GAAP EPS plummeted from $1.79 to $0.41 year-over-year, highlighting pressure on earnings quality that could affect investor confidence.
- Poor Market Performance: Lantheus shares have declined 27% over the past year, significantly underperforming the S&P 500's 15% gain during the same period, suggesting low market expectations for future growth and potentially prompting more investors to reassess their holdings.
See More
Brigade Capital Increases Lantheus Holdings Stake by 173,200 Shares Worth $4.51 Million
- Stake Increase: Brigade Capital Management added 173,200 shares of Lantheus Holdings in Q3, investing $4.51 million, which raised the total stake value to approximately $16.23 million, indicating confidence in the company's future growth potential.
- Asset Allocation: Lantheus Holdings now represents 2.0% of Brigade Capital's 13F reportable assets under management, making it the third-largest holding in the portfolio, reflecting its significance in the investment strategy.
- Financial Performance: Despite a 27% decline in Lantheus's stock price over the past year, the company reported $384 million in revenue and nearly $95 million in free cash flow for Q3, demonstrating its profitability and cash-generating capabilities.
- Strategic Acquisition: During Q3, Lantheus completed the acquisition of Life Molecular Imaging and repurchased $100 million of its own stock while reaffirming full-year revenue guidance of approximately $1.5 billion, indicating a proactive strategic positioning in the market.
See More
Lantheus to Host Q4 and Full Year 2025 Financial Results Call
- Conference Call Announcement: Lantheus Holdings will host a conference call on February 26, 2026, at 8:00 a.m. ET to discuss its financial and operational results for Q4 and the full year of 2025, aiming to provide investors with the latest performance insights.
- Registration Recommendation: The company encourages participants to register online 15 minutes in advance to avoid delays at the start of the call, reflecting its commitment to enhancing the investor experience.
- Replay Availability: A replay will be accessible approximately two hours after the call concludes and will be archived on the same webpage for at least 30 days, allowing investors who could not attend live to access the information, thereby increasing transparency.
- Company Background: Lantheus is a leading radiopharmaceutical-focused company with 70 years of experience, dedicated to enabling clinicians to Find, Fight, and Follow disease, ultimately improving patient outcomes through innovative scientific solutions.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
Lantheus Sells SPECT Business to SHINE, Focuses on PET Radiodiagnostics
- Business Sale: Lantheus has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, which includes diagnostic agents like TechneLite® and NEUROLITE®, marking a strategic shift for the company.
- Focus on Innovation: Post-sale, Lantheus will concentrate on its expanding portfolio of PET radiodiagnostics and microbubbles, which is expected to enhance its competitiveness and innovation in the radiopharmaceutical market.
- Advisory Support: Solomon Partners Securities acted as the financial advisor for Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP provided legal support, ensuring a smooth transaction process.
- Market Outlook: By divesting its SPECT business, Lantheus aims to optimize resource allocation and focus on its high-growth potential PET product line to meet increasing market demand and improve patient treatment outcomes.
See More
Lantheus Sells SPECT Business to SHINE, Focuses on PET Diagnostics
- Business Sale Completed: Lantheus has successfully sold its single photon emission computed tomography (SPECT) business to SHINE Technologies, including several diagnostic agents and the North Billerica, Massachusetts manufacturing facility, which is expected to allow Lantheus to focus more on its rapidly growing PET radiodiagnostics portfolio.
- Strategic Shift: Through this transaction, Lantheus will reallocate resources to innovative PET radiopharmaceuticals and microbubble products, thereby enhancing its competitiveness in the radiopharmaceutical market and driving future R&D advancements.
- Advisory Support: In this transaction, Solomon Partners Securities acted as Lantheus's financial advisor, while Foley Hoag LLP and Ropes & Gray LLP provided legal support, and Ernst & Young LLP handled financial and tax consulting, ensuring a smooth transaction process.
- Market Positioning Optimization: The divestiture of the SPECT business will enable Lantheus to leverage its expertise in radiopharmaceuticals more effectively, further solidifying its market position in cardiac and cancer diagnostics, which is expected to have a positive impact on the company's long-term growth.
See More
Nitorum Capital Exits Lantheus Holdings Stake with $28.2 Million Transaction
- Complete Exit: Nitorum Capital sold 344,444 shares of Lantheus Holdings during Q3 for an estimated $28.2 million, marking a complete exit from the company and reflecting a cautious outlook on its future performance.
- Asset Management Shift: Following this transaction, Nitorum's 13F reportable assets under management decreased to $569.28 million, indicating a significant adjustment in its investment portfolio that may impact future investment strategies.
- Earnings Pressure: Despite Lantheus reporting $384 million in Q3 revenue and nearly $95 million in free cash flow, its GAAP EPS plummeted from $1.79 to $0.41 year-over-year, highlighting pressure on earnings quality that could affect investor confidence.
- Poor Market Performance: Lantheus shares have declined 27% over the past year, significantly underperforming the S&P 500's 15% gain during the same period, suggesting low market expectations for future growth and potentially prompting more investors to reassess their holdings.
See More
Brigade Capital Increases Lantheus Holdings Stake by 173,200 Shares Worth $4.51 Million
- Stake Increase: Brigade Capital Management added 173,200 shares of Lantheus Holdings in Q3, investing $4.51 million, which raised the total stake value to approximately $16.23 million, indicating confidence in the company's future growth potential.
- Asset Allocation: Lantheus Holdings now represents 2.0% of Brigade Capital's 13F reportable assets under management, making it the third-largest holding in the portfolio, reflecting its significance in the investment strategy.
- Financial Performance: Despite a 27% decline in Lantheus's stock price over the past year, the company reported $384 million in revenue and nearly $95 million in free cash flow for Q3, demonstrating its profitability and cash-generating capabilities.
- Strategic Acquisition: During Q3, Lantheus completed the acquisition of Life Molecular Imaging and repurchased $100 million of its own stock while reaffirming full-year revenue guidance of approximately $1.5 billion, indicating a proactive strategic positioning in the market.
See More
